Research Topics
Genomes and Genes | Ghulam J MuftiSummaryAffiliation: King's College London Country: UK Publications
| Collaborators
|
Detail Information
Publications
Pathobiology, classification, and diagnosis of myelodysplastic syndromeGhulam J Mufti
Department of Haematological Medicine, Leukemia Science Laboratories, Guy King s and St Thomas School of Medicine, King s College Hospital, Denmark Hill, SE5 9RS London, UK
Best Pract Res Clin Haematol 17:543-57. 2004..As the functional mechanisms behind these chromosomal changes are being revealed, new therapies based on these mechanisms are currently being made and tested...
Microarray analysis of tumour antigen expression in presentation acute myeloid leukaemiaBarbara Ann Guinn
Department of Haematological Medicine, Guy s, King s and St Thomas School of Medicine, King s College London, London SE5 9NU, UK
Biochem Biophys Res Commun 333:703-13. 2005..We have identified a number of CT antigens with expression in presentation AML samples but not normal donor samples, which may provide effective targets for future immunotherapy treatments early in disease...
CD38 expression in chronic lymphocytic leukemia is regulated by the tumor microenvironmentPiers E M Patten
Department of Haematological and Molecular Medicine, King s College London, Rayne Institute, London, USA
Blood 111:5173-81. 2008....
Myelodysplastic syndromes: who and when in the course of disease to transplantGhulam J Mufti
Department of Haematological Medicine, King s College London, London, United Kingdom
Hematology Am Soc Hematol Educ Program 2012:49-55. 2012....
Changing the treatment paradigm in myelodysplastic syndromesGhulam J Mufti
Kings College London and Kings College Hospital, Department of Haematological Medicine, London SE5 9RS UK
Cancer Control 15:14-28. 2008..Timing of available therapies, including stem cell transplantation, should be incorporated into the new treatment paradigm, with end goals of prolonging survival and optimizing patient outcomes...
Diagnosis and classification of myelodysplastic syndrome: International Working Group on Morphology of myelodysplastic syndrome (IWGM-MDS) consensus proposals for the definition and enumeration of myeloblasts and ring sideroblastsGhulam J Mufti
Department of Haematology, King s College Hospital, Denmark Hill, London, SE5 9RS United Kingdom
Haematologica 93:1712-7. 2008..Recommendations should be applied in the context of the WHO classification...
TP53 mutations in myelodysplastic syndrome are strongly correlated with aberrations of chromosome 5, and correlate with adverse prognosisAustin G Kulasekararaj
Department of Haematological Medicine, King s College London, School of Medicine, London, UK
Br J Haematol 160:660-72. 2013..The relatively common occurrence of these mutations in two different prognostic spectrums of MDS, i.e. isolated 5q- and CK with -5/5q-, possibly implies two different mechanistic roles for TP53 protein...
Next-generation sequencing of the TET2 gene in 355 MDS and CMML patients reveals low-abundance mutant clones with early origins, but indicates no definite prognostic valueAlexander E Smith
Department of Hematologic Medicine, King s College London School of Medicine, London, United Kingdom
Blood 116:3923-32. 2010..On multivariate analysis, age (> 50 years) was associated with a higher incidence of TET2 mutation (P = .02)...
Rapid recovery of lymphocyte subsets is not associated with protection from relapse of myelodysplastic syndromes and acute myeloid leukaemia after haematopoietic stem cell transplantation using a reduced intensity conditioning regimen and alemtuzumabKatie Matthews
The Anthony Nolan Research Institute, Royal Free Hospital, London, UK
Br J Haematol 149:879-89. 2010....
A functional assay for microRNA target identification and validationJoop Gaken
Department of Haematological Medicine, King s College London, Rayne Institute, London SE5 9NU, UK
Nucleic Acids Res 40:e75. 2012..Identification of MAFB and five additional targets and their subsequent confirmation as mir-130a targets by western blot analysis and knockdown experiments validates this strategy for the functional identification of miRNA targets...
Alemtuzumab with fludarabine and cyclophosphamide reduces chronic graft-versus-host disease after allogeneic stem cell transplantation for acquired aplastic anemiaJudith C Marsh
Department of Hematological Medicine, King s College Hospital King s College London, London, UK
Blood 118:2351-7. 2011..001) and age (92% for age < 50 years vs 71% ≥ 50 years, P < .001). Our data suggest that the use of an alemtuzumab-based HSCT regimen for SAA results in durable engraftment with a low incidence of chronic GVHD...
Proteomic and protein interaction network analysis of human T lymphocytes during cell-cycle entryStephen J Orr
Department of Haematological Medicine, Leukaemia Sciences Laboratories, Rayne Institute, King s College London, UK
Mol Syst Biol 8:573. 2012....
Inhibitors of poly ADP-ribose polymerase (PARP) induce apoptosis of myeloid leukemic cells: potential for therapy of myeloid leukemia and myelodysplastic syndromesTerry J Gaymes
Department of Haematological, Medicine, King s College, London, The Rayne Institute, 123 Coldharbour Lane, London, UK
Haematologica 94:638-46. 2009....
Human CD80/IL2 lentivirus-transduced acute myeloid leukaemia (AML) cells promote natural killer (NK) cell activation and cytolytic activity: implications for a phase I clinical studyWendy Ingram
Department of Haematological Medicine, King s College London, London, UK
Br J Haematol 145:749-60. 2009..4% to 22.5%). These studies demonstrated that vaccination of patients with CD80/IL2-transduced AML cells could provide a powerful strategy for T/NK cell-mediated stimulation of anti-leukaemic immunological responses...
Phase II study on combination therapy with CHOP-Zenapax for HTLV-I associated adult T-cell leukaemia/lymphoma (ATLL)M Mansour Ceesay
Department of Haematological Medicine, King s College Hospital NHS Foundation Trust and King s College London, London, UK
Leuk Res 36:857-61. 2012..In conclusion CHOP-Z is safe and in those who achieve a complete response it was associated with prolonged overall survival...
Functional characterization of CD4+ T cells in aplastic anemiaShahram Kordasti
Department of Haematological Medicine, King s College London, Rayne Institute, 123 Coldharbour Lane, London, United Kingdom
Blood 119:2033-43. 2012..The clonally restricted expansion of Th1 cells is most likely to be antigen-driven, and induces an inflammatory environment, that exacerbate the functional impairment of Tregs, which are reduced in number...
The use of PARP inhibitors in cancer therapy: use as adjuvant with chemotherapy or radiotherapy; use as a single agent in susceptible patients; techniques used to identify susceptible patientsSydney Shall
Department of Haematological Medicine, The Rayne Institute, Kings College London, Denmark Hill Campus, London, UK
Methods Mol Biol 780:239-66. 2011....
Interaction with vascular endothelium enhances survival in primary chronic lymphocytic leukemia cells via NF-kappaB activation and de novo gene transcriptionAndrea G S Buggins
Department of Haematological Medicine, King s College London, London, United Kingdom
Cancer Res 70:7523-33. 2010..This type of interaction in the peripheral vasculature may explain the constitutive NF-κB activation and the overexpression of Bcl-2 family proteins commonly seen in this disease...
Chromosomal instability syndromes are sensitive to poly ADP-ribose polymerase inhibitorsTerry J Gaymes
Department of Haematological Medicine, Leukaemia Sciences Laboratories, The Rayne Institute, Kings College London, Denmark Hill Campus, London, UK
Haematologica 93:1886-9. 2008....
Humoral detection of leukaemia-associated antigens in presentation acute myeloid leukaemiaBarbara Ann Guinn
Department of Haematological Medicine, Guy s, King s and St Thomas School of Medicine, King s College London, The Rayne Institute, 123 Coldharbour Lane, London SE5 9NU, UK
Biochem Biophys Res Commun 335:1293-304. 2005..Antigen presentation assays using monocyte-derived dendritic cells (mo-DCs) showed that PASD1 could stimulate autologous T-cell responses, suggesting that PASD1 could be a promising target for future immunotherapy clinical trials...
Optimised SEREX technique for the identification of leukaemia-associated antigensBarbara Ann Guinn
Leukaemia Science Laboratories, Department of Haematological Medicine, Guy s, King s and St Thomas School of Medicine, Denmark Hill Campus, Rayne Institute, 123 Coldharbour Lane, London, UK
J Immunol Methods 264:207-14. 2002..Using the methodology described, we have shown SEREX to be effective for the isolation of leukaemia-associated antigens, which may act as targets for immunotherapy...
Increased error-prone NHEJ activity in myeloid leukemias is associated with DNA damage at sites that recruit key nonhomologous end-joining proteinsNicola Brady
Department of Haematological Medicine, Leukaemia Sciences Laboratories, The Rayne Institute, Guy's, King's, St. Thomas' School of Medicine, Denmark Hill, London SE5 9NU, United Kingdom
Cancer Res 63:1798-805. 2003..These data suggest that the generation of increased constitutive DNA damage may be a common pathway for the creation of NHEJ-dependent genomic instability...
High efficiency protein transduction of quiescent and proliferating primary hematopoietic cellsNicholas C Lea
Department of Haematological Medicine, Guy s, King s and St Thomas School of Medicine, Rayne Institute, 123 Coldharbour Lane, London, SE5 9NU, UK
J Biochem Biophys Methods 55:251-8. 2003..This method will allow us to study of the effects of a variety of gene products in cell types that were previously resistant to gene transfection studies...
Antiapoptotic microenvironment of acute myeloid leukemiaDragana Milojkovic
Department of Haematological Medicine, Leukaemia Sciences, Guy s, King s and St Thomas School of Medicine, Rayne Institute, London, United Kingdom
J Immunol 173:6745-52. 2004..Reversal of these immunosuppressive effects and restoration of normal immune responses in patients with AML would improve the success of immunotherapy protocols...
Cyclin D2 controls B cell progenitor numbersAzim Mohamedali
Leukaemia Sciences, Guy s, King s, St Thomas School of Medicine, Rayne Institute, 123 Coldharbour Lane, London SE5 9RS, UK
J Leukoc Biol 74:1139-43. 2003..We conclude that cyclin D2 is rate-limiting for the production of B lymphoid progenitor cells whose proliferation does not depend on BCR signaling...
Constitutive DNA damage is linked to DNA replication abnormalities in Bloom's syndrome cellsFeyruz V Rassool
Department of Haematological Medicine, The Rayne Institute, Guy s, King s and Thomas School of Medicine, 123 Coldharbour Lane, London SE5 9NU, UK
Oncogene 22:8749-57. 2003..Thus, our data indicate that constitutive DNA damage is coupled to delayed DNA replication in BS cells...
Outcome of donor lymphocyte infusion after T cell-depleted allogeneic hematopoietic stem cell transplantation for acute myelogenous leukemia and myelodysplastic syndromesPramila Krishnamurthy
Department of Haematological Medicine, King s College Hospital, London, UK
Biol Blood Marrow Transplant 19:562-8. 2013..We demonstrate that pDLI safely promotes durable remission after TCD RIC HSCT for AML or MDS, and that tDLI salvages patients after late relapse with greater efficacy...
Prevalence and clinical outcomes of the 46/1 haplotype, Janus kinase 2 mutations, and ten-eleven translocation 2 mutations in Budd-Chiari syndrome and their impact on thrombotic complications post liver transplantationRachel H Westbrook
Institute of Liver Studies, King s College Hospital, National Health Service Foundation Trust, London, United Kingdom
Liver Transpl 18:819-27. 2012..005). In conclusion, the presence of JAK2V617F predicts hepatic and extrahepatic thrombotic complications after LT. Testing for TET2 mutations can identify another 7% of idiopathic BCS patients with molecular MPDs...
Prospective study of rabbit antithymocyte globulin and cyclosporine for aplastic anemia from the EBMT Severe Aplastic Anaemia Working PartyJudith C Marsh
Department of Haematological Medicine, King s College Hospital King s College London, London, United Kingdom
Blood 119:5391-6. 2012..9, P = .003) and age more than 37 years (hazard ratio = 4.7, P = .0008) were independent adverse risk factors for survival. This study was registered at www.clinicaltrials.gov as NCT00471848...
Fluorescence-based experimental model to evaluate the concomitant effect of drugs on the tumour microenvironment and cancer cellsKarthik Ramasamy
Division of Cancer Studies, Department of Haematological Medicine, Kings College London, UK
Br J Haematol 157:564-79. 2012..This new experimental platform provides a more precise screening of new therapeutics for improved efficacy of tumour cell killing within the bone marrow microenvironment...
Human CD80/IL2 lentivirus transduced acute myeloid leukaemia cells enhance cytolytic activity in vitro in spite of an increase in regulatory CD4+ T cells in a subset of culturesWendy Ingram
Department of Haematological Medicine, King s College London, Rayne Institute, 123 Coldharbour Lane, London, SE5 9NU, UK
Cancer Immunol Immunother 58:1679-90. 2009..Vaccination with LV-CD80/IL2 therefore provides a potential strategy to enhance anti-leukaemia immune responses without a concomitant stimulation of Treg-mediated inhibition of cytotoxic immunological responses...
Delayed attainment of full donor chimaerism following alemtuzumab-based reduced-intensity conditioning haematopoeitic stem cell transplantation for acute myeloid leukaemia and myelodysplastic syndromes is associated with improved outcomesZi Yi Lim
Department of Haematological Medicine, Kings College London and Kings College Hospital, Denmark Hill, London, UK
Br J Haematol 138:517-26. 2007..Future studies need to be directed towards establishing the underlying factors that dictate T-cell engraftment, expansion and homing post-transplantation...
Myeloid leukemias have increased activity of the nonhomologous end-joining pathway and concomitant DNA misrepair that is dependent on the Ku70/86 heterodimerTerry J Gaymes
Department of Haematological Medicine, Leukaemic Sciences Laboratories, The Rayne Institute, GKT School of Medicine, Denmark Hill, London SE5 9NU, UK
Cancer Res 62:2791-7. 2002..Our findings suggest that an overactive NHEJ system and, specifically, aberrant Ku70/86 activity is a candidate mechanism for chromosomal instability in myeloid leukemias...
Reduced-intensity allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome and acute myeloid leukemia with multilineage dysplasia using fludarabine, busulphan, and alemtuzumab (FBC) conditioningAloysius Y L Ho
Department of Haematological Medicine, King's College Hospital, Denmark Hill, London SE5 9RS, United Kingdom
Blood 104:1616-23. 2004..RIC allogeneic HSCT using this protocol appears to be safe and permits durable donor engraftment. Longer follow-up is required to confirm any potential survival advantage...
IL-17-producing CD4(+) T cells, pro-inflammatory cytokines and apoptosis are increased in low risk myelodysplastic syndromeShahram Y Kordasti
Department of Haematological Medicine, King s College London, The Rayne Institute, London, UK
Br J Haematol 145:64-72. 2009..The 'unfavourable' Th17:Tregs ratio in low risk MDS may explain the higher risk of autoimmunity and the improved response to immune suppression in patients with low risk MDS compared to those with high risk disease...
Van-den Berghe's 5q- syndrome in 2008Azim Mohamedali
Department of Haematological Medicine, Kings College London, London, UK
Br J Haematol 144:157-68. 2009..This review examines the potential role of several genes, including RPS14, in the pathogenesis of the 5q- syndrome and recent advances in clinical management, with particular emphasis on the role and mechanism of action of lenalidomide...
Epigenetics of human T cells during the G0-->G1 transitionAlexander E Smith
King s College London, Department of Haematological Medicine, Leukaemia Sciences Laboratories, Rayne Institute, London, United Kingdom
Genome Res 19:1325-37. 2009..Furthermore, a drop in meC also marks 3' transcription termination, and a peak of meC occurs at stop codons. This mimics the 3' nucleosomal distribution in yeast, which we show does not occur in human T cells...
Allogeneic hematopoietic stem-cell transplantation for patients 50 years or older with myelodysplastic syndromes or secondary acute myeloid leukemiaZiYi Lim
Department of Haematological Medicine, Kings College London and Kings College Hospital, Denmark Hill, London, United Kingdom
J Clin Oncol 28:405-11. 2010....
Imbalance of effector and regulatory CD4 T cells is associated with graft-versus-host disease after hematopoietic stem cell transplantation using a reduced intensity conditioning regimen and alemtuzumabKatie Matthews
Anthony Nolan Research Institute, Royal Free Hospital, London, UK
Haematologica 94:956-66. 2009....
Peripheral blood but not tissue dendritic cells express CD52 and are depleted by treatment with alemtuzumabAndrea G S Buggins
Department of Haematological Medicine, Guy's, King's and Thomas' School of Medicine, Denmark Hill, London, England
Blood 100:1715-20. 2002....
Outcome of BEAM-autologous and BEAM-alemtuzumab allogeneic transplantation in relapsed advanced stage follicular lymphomaWendy Ingram
Department of Haematological Medicine, King s College London and Kings College Hospital, London, UK
Br J Haematol 141:235-43. 2008..Furthermore, the ability to re-induce remissions with donor leucocytes provides additional benefit in favour of allogeneic HSCT...
An immune edited tumour versus a tumour edited immune system: Prospects for immune therapy of acute myeloid leukaemiaLucas Chan
King's College London, Department of Haematological Molecular Medicine, The Rayne Institute, 123 Coldharbour Lane, SE5 9NU, London, UK
Cancer Immunol Immunother 55:1017-24. 2006....
Increased error-prone non homologous DNA end-joining--a proposed mechanism of chromosomal instability in Bloom's syndromeTerry J Gaymes
Department of Haematological Medicine, Leukaemic Sciences Laboratories, The Rayne Institute, GKT School of Medicine, Denmark Hill, London SE5 9NU, UK
Oncogene 21:2525-33. 2002..This aberrant repair is dependent upon the presence of the Ku70/86 heterodimer, a key component in the NHEJ pathway. We propose that aberrant NHEJ is a candidate mechanism for the generation of chromosomal instability in BS...
Targeted therapies in myeloid leukemiaAlison M John
Leukaemia Sciences Laboratories, Department of Haematological Medicine, Guy's, King's and St Thomas' School of Medicine, King's College London, The Rayne Institute, 123 Coldharbour Lane, London SE5 9NU, UK
Semin Cancer Biol 14:41-62. 2004....
Outcomes of alemtuzumab-based reduced intensity conditioning stem cell transplantation using unrelated donors for myelodysplastic syndromesZi Yi Lim
Department of Haematological Medicine, Kings College London and Kings College Hospital, UK
Br J Haematol 135:201-9. 2006..RIC regimens using VUD was associated with durable long-term survival even in older patients with MDS, and the use of a pre-transplant comorbidity index may help to improve patient selection for transplantation...
Histone deacetylase inhibitors (HDI) cause DNA damage in leukemia cells: a mechanism for leukemia-specific HDI-dependent apoptosis?Terry J Gaymes
Department of Haematological Medicine, Leukemia Sciences Laboratories, The Rayne Institute, GKT School of Medicine, Denmark Hill Campus, London, United Kingdom
Mol Cancer Res 4:563-73. 2006..Our data indicate that induction of apoptosis by HDI may result predominantly through accumulation of excessive DNA damage in leukemia cells, leading to activation of apoptosis...
CD4+CD25high Foxp3+ regulatory T cells in myelodysplastic syndrome (MDS)Shahram Y Kordasti
Department of Hematological Medicine, King s College London, Rayne Institute, 123 Coldharbour Lane, London, UK
Blood 110:847-50. 2007..032). Our data suggest that CD4+ Treg expansion is a feature of high-risk MDS and progression to aggressive subtypes of the disease...
Prevalence of the activating JAK2 tyrosine kinase mutation V617F in the Budd-Chiari syndromeRaj K Patel
Department of Haematological Medicine, King s College Hospital, London, England
Gastroenterology 130:2031-8. 2006..A clonal mutation in JAK2 tyrosine kinase (JAK2V617F) occurs in a high proportion of patients with MPD and is of use in the characterization of latent MPD in BCS...
Toxoplasmosis following alemtuzumab based allogeneic haematopoietic stem cell transplantationZiYi Lim
Department of Haematological Medicine, Kings College London and Kings College Hospital, Denmark Hill SE5 9RS, UK
J Infect 54:e83-6. 2007..9% and 3.0% respectively. Despite in vivo T-cell depletion with alemtuzumab, the incidence of toxoplasma disease in our cohort was comparable with previously reported T-cell replete HSCT studies...
The Non-transplant Treatment of Myelodysplastic Syndromes-What's on the Horizon?Austin G Kulasekararaj
Department of Haematological Medicine, King s College London School of Medicine, London, UK Department of Haematology, King s College Hospital, London, UK
Semin Hematol 49:350-60. 2012....
Novel TET2 mutations associated with UPD4q24 in myelodysplastic syndromeAzim M Mohamedali
Department of Haematological Medicine, King s College London School of Medicine, London, UK
J Clin Oncol 27:4002-6. 2009..We investigated the sequence integrity of 4q24 candidate tumor suppressor gene TET2 in MDS patients with UPD on chromosome 4...
Anti-tumor immunity in a model of acute myeloid leukemiaAdam T C Cheuk
Department of Haematological Medicine, Allergy and Respiratory Science, MRC Asthma UK Centre in Allergic Mechanisms of Asthma, King s College London School of Medicine, London, UK
Leuk Lymphoma 50:447-54. 2009..In human allogeneic mixed lymphocyte reactions (MLRs), we found no single costimulatory molecule was more effective, suggesting that the induction of a universal anti-tumor response will require a combination of costimulatory molecules...
Effects on erythropoiesis of alemtuzumab-containing reduced intensity and standard conditioning regimensAleksandar Mijovic
Department of Haematological Medicine, King s College Hospital, London, UK
Br J Haematol 142:444-52. 2008..However, transfusion requirements were significantly higher in the SCo group, due at least partly to earlier onset of bone marrow hypoplasia...
Allogeneic stem cell transplantation in the myelodysplastic syndromes: interim results of outcome following reduced-intensity conditioning compared with standard preparative regimensJane E Parker
Department of Haematological Medicine, Guy's, King's, Thomas' School of Medicine, London, UK
Br J Haematol 119:144-54. 2002..5 year DFS to those receiving conventional regimens...
Outcomes of patients with haematological malignancies admitted to intensive care unit. A comparative review of allogeneic haematopoietic stem cell transplantation dataZiYi Lim
Haematological Medicine, Kings College London and Kings College Hospital, London, UK
Br J Haematol 136:448-50. 2007..10%, P = 0.19). None of the nine myeloablative HSCT recipients survived (median survival: 9 d). Six of the 15 reduced-intensity conditioned HSCT recipients survived beyond 1 year (median survival: 1050 d, range: 438-1437)...
Prevalence and prognostic significance of allelic imbalance by single-nucleotide polymorphism analysis in low-risk myelodysplastic syndromesAzim Mohamedali
Department of Haematological Medicine, King s College Hospital, King s College London School of Medicine, Denmark Hill, London, United Kingdom
Blood 110:3365-73. 2007..001). We show, for the first time, that SNP microarray analysis in low-risk MDS patients reveals hitherto unrecognized UPD and CN changes that may allow stratification of these patients for early therapeutic interventions...
Allogeneic transplantation for myelodysplastic syndrome (MDS)Wendy Ingram
Department of Haematological Medicine, Kings College Hospital and Kings College London, Denmark Hill, London, SE5 9RS, UK
Blood Rev 21:61-71. 2007..The graft versus dysplasia effect resulting from allogeneic HSCT and the infusion of donor leukocytes has led to a greater understanding of the immunological mechanisms that govern outcome following transplantation in MDS...
Apoptosis in the myelodysplastic syndromesNigel B Westwood
Department of Haematology, King's College Hospital, Denmark Hill, London SE5 9RS, UK
Curr Hematol Rep 2:186-92. 2003..Expression profiling and proteomic technologies may offer the best means to unravel this process...
Development of a whole cell vaccine for acute myeloid leukaemiaAdam T C Cheuk
Department of Haematological Medicine, Guy's, King's and St. Thomas' School of Medicine, The Rayne Institute, King's College London, 123 Coldharbour Lane, London, SE5 9NU, UK
Cancer Immunol Immunother 55:68-75. 2006..We will aim to provide a brief overview of the latest data from our group and considerations for the use of this treatment modality in clinical trials for AML...
Role of 4-1BB:4-1BB ligand in cancer immunotherapyAdam T C Cheuk
Leukaemia Science Laboratories, Department of Haematological Medicine, Guy's, King's and St Thomas' School of Medicine, King's College London, Rayne Institute, 123 Coldharbour Lane, London SE5 9NU, UK
Cancer Gene Ther 11:215-26. 2004..In particular, we will describe the structure and function of the 4-1BB molecule, its receptor and how 4-1BB:4-1BBL costimulation has and may be used for the immunotherapy of cancer...
Liver transplantation for HCV-related cirrhosis in a patient with gastric mucosa-associated lymphoma (MALToma) pretreated with rituximabMatthew R Foxton
Institute of Liver Studies, King s College Hospital, London SE5 9RS, UK
Liver Transpl 11:839-42. 2005..Rituximab may be useful in preventing progression of NHL until surgical extirpation is possible...
AKT1 (E17K) mutation in pancreatic cancerAzim Mohamedali
Department of Haematological Medicine, Kings College London, 123 Coldharbour Lane, London
Technol Cancer Res Treat 7:407-8. 2008..This mutation was un-detectable in pancreatic cancer tissue samples (n=65) and pancreatic cell line (n=10) DNA suggesting that pancreatic cancer progression is mainly dependent on the K-Ras mutation...
The myelodysplastic syndromes: a matter of life or deathJane E Parker
Department of Haematological Medicine, Norfolk and Norwich University Hospital, Norwich, UK
Acta Haematol 111:78-99. 2004..This paper outlines the apoptotic process in normal hematopoietic cells and summarizes current data regarding the role, potential causes and clinical implications of altered apoptosis in MDS...
T-cell lymphoblastic lymphoma presenting as an intra-muscular massZiYi Lim
Department of Haematological Medicine, Kings College London and Kings College Hospital, UK
Br J Haematol 132:537. 2006
Eczematoid graft-vs-host disease: a novel form of chronic cutaneous graft-vs-host disease and its response to psoralen UV-A therapyDaniel Creamer
Department of Dermatology, King s College Hospital, Denmark Hill, London SE5 9RS, England
Arch Dermatol 143:1157-62. 2007..Within a large population of individuals who underwent allogeneic stem cell transplantation because of hematologic malignancy, a group of patients was identified in whom severe and persistent eczema developed...
Analysis of CHK2 in patients with myelodysplastic syndromesDilek Aktas
Department of Genetics, Hacettepe University Children's Hospital, , Ankara, Turkey
Leuk Res 26:985-7. 2002..We conclude that alterations of CHK2 and possible involvement in the pathogenesis of MDS may be a rare event...
Commitment point during G0-->G1 that controls entry into the cell cycleNicholas C Lea
Department of Haematological Medicine, Leukaemia Sciences Laboratories, Guy's, King's and St. Thomas' School of Medicine, London SE5 9NU, United Kingdom
Mol Cell Biol 23:2351-61. 2003....
Direct transcriptional regulation of Bim by FoxO3a mediates STI571-induced apoptosis in Bcr-Abl-expressing cellsAbdelkader Essafi
Cancer Research UK Labs, Department of Cancer Medicine, MRC Cyclotron Building, Imperial College London, Hammersmith Hospital, Du Cane Road, London W12 0NN, UK
Oncogene 24:2317-29. 2005..Thus, STI571 induces an accumulation of FoxO3a activity which in turn binds directly to an FHRE in the promoter to activate Bim expression and apoptosis...
BCL-2 and mutant NRAS interact physically and functionally in a mouse model of progressive myelodysplasiaNader Omidvar
Institut National de la Sante et de la Recherche Medicale U718 and 728, Universite Paris 7 Denis Diderot, Faculte de Medicine, Institut Universitaire d Hématologie IFR105, Paris, France
Cancer Res 67:11657-67. 2007..The colocalization of BCL-2 and RAS in the bone marrow of MDS/AML patients offers targeting either oncogene as a therapeutic strategy...
The tumour antigens RAGE-1 and MGEA6 are expressed more frequently in the less lineage restricted subgroups of presentation acute myeloid leukaemiaBarbara-Ann Guinn
Br J Haematol 134:238-9. 2006
Reactive oxygen species, DNA damage, and error-prone repair: a model for genomic instability with progression in myeloid leukemia?Feyruz V Rassool
Department of Radiation Oncology, University of Maryland School of Medicine, Baltimore, Maryland 21201 1509, USA
Cancer Res 67:8762-71. 2007..These data suggest treatment strategies that target RAS/RAC pathways and ROS production in human MDS/AML...
Myelodysplastic syndromes (MDSs) and acute myelogenous leukemia (AML) comprise a closely linked continuum of malignant hematologic diseases. IntroductionStephen B Baylin
Cancer Biology Division at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Johns Hopkins University School of Medicine, Baltimore, MD, USA
Nat Clin Pract Oncol 2:S1-3. 2005
P15INK4B is not mutated in adult familial myelodysplastic syndromesElizabeth Cameron
Br J Haematol 119:277-9. 2002
High incidence of therapy-related myelodysplasia and acute leukaemia in general haematology clinic patients treated with fludarabine and cyclophosphamide for indolent lymphoproliferative disordersStella J Bowcock
Br J Haematol 134:242-3. 2006
Retrospective comparison of reduced-intensity conditioning and conventional high-dose conditioning for allogeneic hematopoietic stem cell transplantation using HLA-identical sibling donors in myelodysplastic syndromesRodrigo Martino
Division of Clinical Hematology, Hopital de la Sant Creu i Sant Pau, Autonomous University of Barcelona, Spain
Blood 108:836-46. 2006....
Impact of the intensity of the pretransplantation conditioning regimen in patients with prior invasive aspergillosis undergoing allogeneic hematopoietic stem cell transplantation: A retrospective survey of the Infectious Diseases Working Party of the EuroRodrigo Martino
Hematology Department of Sant Pau Hospital, Autonomous University of Barcelona, Spain
Blood 108:2928-36. 2006..001]). These findings may help in the interpretation and design of future studies on secondary prophylaxis of IA after an allo-HSCT...
Practical recommendations on the use of lenalidomide in the management of myelodysplastic syndromesAristoteles Giagounidis
St Johannes Hospital, Medizinische Klinik II, An der Abtei 7 11, 47166 Duisburg, Germany
Ann Hematol 87:345-52. 2008....
A multicenter phase 2 study of the farnesyltransferase inhibitor tipifarnib in intermediate- to high-risk myelodysplastic syndromePierre Fenaux
Hopital Avicenne, Paris, France
Blood 109:4158-63. 2007..In this study, durable responses and acceptable side effects were observed. Tipifarnib is an active agent for the treatment of patients with intermediate- to high-risk MDS...
The leukaemia-associated antigen, SSX2IP, is expressed during mitosis on the surface of myeloid leukaemia cellsFrances A K Denniss
Br J Haematol 138:668-9. 2007
Methylation inhibitor therapy in the treatment of myelodysplastic syndromeLewis R Silverman
Myelodisplastic Syndrome/Myeloproliferative Disease Center, Mount Sinai School of Medicine, NewYork, NY, USA
Nat Clin Pract Oncol 2:S12-23. 2005..g. according to age, risk, classification, and cytogenetic profile), and the combination strategies, particularly with histone deacetylase inhibitors, in the management of MDS...
Emerging therapeutic and supportive care approaches for the myelodisplastic syndromesGhulam J Mufti
Rev Clin Exp Hematol 8:E4. 2004
Mobilization of hematopoietic progenitors in low-grade myelodysplastic syndromesAleksandar Mijovic
Haematologica 91:572-3. 2006..Only three out of 15 patients had adequate progenitor cell collections for potential use in autologous transplantation...
